Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mustard gas-induced lung edema was significantly reduced by AEOL 10150 as measured by bronchoalveolar lavage protein levels
Subscribe to our email newsletter
Aeolus Pharmaceuticals (Aeolus) has reported that AEOL 10150 protects lungs from whole mustard gas exposure in rats, based on the series of preliminary studies conducted by National Jewish Health and Lovelace Respiratory Research Institute. AEOL 10150 is an effective treatment for mustard gas exposure, said the company.
Reportedly, to determine whether administration of AEOL 10150 after exposure reduces the severity of acute lung injury induced by mustard gas, was the major objective of this study.
In the study, one hour after sulfur mustard vapor exposure AEOL 10150 was given to rats and repeated every 6 hours. Lung edema was assessed by changes in the bronchoalveolar lavage (BAL) protein levels after twenty-four hours of exposure.
The study result suggested that mustard gas-induced lung edema was significantly reduced by AEOL 10150 as measured by bronchoalveolar lavage protein levels. AEOL 10150 has also decreased SM-induced increase in the numbers of BAL neutrophils.
Moreover, these results indicate that AEOL 10150 attenuates lung injury from mustard gas exposure and provides an effective countermeasure against mustard gas-induced lung injury.
Significant protective effects against radiation and mustard gas were shown by AEOL 10150 animal models. It is believed that the compound, based on its mechanism, may potentially protect against exposure to chlorine gas.
Carl White, pediatric pulmonologist at National Jewish and director of the CounterACT Center of Excellence in Denver, said: “We are very impressed with the robust effects of AEOL 10150 in rescuing the lung against the deleterious effects of sulfur mustard vapor. These data affirm our earlier studies where AEOL 10150 protected the lung against the half-mustard, 2-chloroethyl ethylsufide.”
John McManus, president and CEO of Aeolus, said: “AEOL 10150 continues to perform well in the mustard studies, and shows promise as a potential treatment for exposure to multiple terrorist threats, including mustard gas, radiation and chlorine gas. Further NIH-funded studies to confirm the results obtained in this pilot study of whole mustard are expected to begin shortly.”